Advancements in Pharmacotherapy and Mobile Health Applications for Self-Management in Multiple Sclerosis: A Comprehensive Review - PubMed
6 hours ago
- #Pharmacotherapy
- #Mobile Health
- #Multiple Sclerosis
- Multiple sclerosis (MS) is a chronic autoimmune disorder affecting nearly three million people globally.
- Pharmacotherapy and treatment adherence are crucial for relapse prevention and disability progression in MS.
- Injectable therapies like interferons and glatiramer acetate reduce ARR by 30% with good safety profiles.
- Oral agents (fingolimod, dimethyl fumarate, teriflunomide, cladribine) reduce ARR by 45-55% with better adherence but require periodic lab monitoring.
- Monoclonal antibodies (natalizumab, ocrelizumab) achieve up to 68% relapse reduction but require close surveillance for risks like PML and infections.
- Oral DMTs offer a balanced compromise for long-term MS management due to efficacy and practicality.
- Mobile health applications can enhance self-monitoring, adherence, and disease awareness in MS patients.
- Integration of biotechnology, tele-neurology, and AI analytics is the future of personalized MS care.
- Monoclonal antibodies represent the highest efficacy in current MS therapy but require safety oversight.
- The synergy between pharmacotherapy and mobile health technology can optimize MS management outcomes.